A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure.

Trial Profile

A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Aviscumine (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Cytavis BioPharma
  • Most Recent Events

    • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 22 Feb 2012 Planned number of patients changed from 29 to 32 as reported by European Clinical Trials Database.
    • 25 Aug 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2007-000427-17).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top